rs150090666 — PDE3B PDE3B R783X

Loss-of-function variant in phosphodiesterase 3B — carriers have enhanced cAMP-mediated lipolysis, higher HDL cholesterol, lower triglycerides, and reduced cardiovascular disease risk

See your personal result for PDE3B

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PDE3B — The Lipolysis Brake Gene

Your fat cells hold a carefully balanced switch between storing and releasing fat. Phosphodiesterase 3B (PDE3B) is the enzyme that applies the brake. It degrades cAMP11 cAMP
cyclic adenosine monophosphate, a second messenger that activates hormone-sensitive lipase and triggers fat breakdown in adipocytes. When PDE3B functions normally, it limits how strongly stress hormones like adrenaline can stimulate fat burning — a regulatory safeguard that in some contexts becomes a metabolic bottleneck. Carriers of the rare R783X loss-of-function variant have a partially disabled brake, which translates into measurably different lipid profiles and fat distribution patterns compared to the general population.

The Mechanism

The rs150090666 C>T variant introduces a premature stop codon at amino acid position 783, truncating the PDE3B protein within its catalytic domain (p.Arg783Ter). The truncated protein lacks the C-terminal portion needed for full phosphodiesterase activity. With a partially or fully inactive PDE3B, cAMP accumulates more readily in adipocytes in response to catecholamines (epinephrine, norepinephrine) and glucagon, sustaining protein kinase A (PKA) signaling longer than normal. PKA phosphorylates hormone-sensitive lipase (HSL)22 PKA phosphorylates hormone-sensitive lipase (HSL)
HSL is the enzyme that cleaves triglycerides stored in fat droplets into free fatty acids for export, so elevated cAMP drives enhanced lipolysis. The net effect is a shift away from visceral fat storage and toward a more favorable lipid phenotype.

The Evidence

The most detailed human evidence comes from Koprulu et al. (2022, PMID 34875679)33 Koprulu et al. (2022, PMID 34875679), who examined rare loss-of-function variants across 450,562 UK Biobank participants. The PDE3B p.R783X variant (rs150090666, T allele frequency ~0.1%) was significantly associated with lower waist-to-hip ratio adjusted for BMI (WHRadjBMI; P = 1.41 × 10⁻⁶), with a beta of −0.39 standard deviations in women and −0.10 in men — a sex-biased effect consistent with sex differences in fat distribution genetics more broadly. The variant was also associated with lower triglycerides, higher HDL cholesterol, higher apolipoprotein A1, and a statistically significant reduction in cardiovascular disease risk when meta-analyzed across multiple cohorts.

Tanigawa et al. (2019, PMID 31492854)44 Tanigawa et al. (2019, PMID 31492854) independently identified rs150090666 as a protein-truncating variant substantially contributing to obesity-related traits across 2,138 phenotypes in 337,199 UK Biobank participants, and demonstrated PDE3B expression rises sharply during adipogenesis in both mouse (3T3-L1) and human (SGBS) adipocytes — consistent with a primary role in mature fat cell biology. Agrawal et al. (2022, PMID 35773277)55 Agrawal et al. (2022, PMID 35773277) replicated the fat distribution association and showed the effect is most prominent in the gluteofemoral depot, a pattern linked to lower cardiometabolic risk. A complementary GWAS in African ancestry populations Ng et al. 2017, PMID 2843082566 Ng et al. 2017, PMID 28430825 confirmed PDE3B as a locus for WHRadjBMI, with novel associations in women.

At the cellular level, DiPilato et al. (2015, PMID 26031333)77 DiPilato et al. (2015, PMID 26031333) showed that adipocytes genetically lacking PDE3B cannot suppress lipolysis in response to insulin, confirming PDE3B's central role in cAMP-mediated fat regulation. Mowers et al. (2013, PMID 24368730)88 Mowers et al. (2013, PMID 24368730) demonstrated that chronic inflammation in obesity hyper-activates PDE3B through IKKε and TBK1 kinases, blunting cAMP signaling and causing catecholamine resistance — precisely the pathway that loss of PDE3B function circumvents.

Practical Actions

Carriers of the T allele (CT heterozygotes) carry one partially inactivated PDE3B copy. The phenotypic signal — higher HDL, lower triglycerides, favorable fat distribution — is real and measurable in large population studies. The effect size for a single copy is modest (lipid differences of a few mg/dL; WHRadjBMI beta of approximately −0.10 in pooled analyses), but the direction is consistently favorable for cardiovascular risk. Carriers should confirm these benefits are reflected in their actual lipid panel. If triglycerides or HDL are unexpectedly outside the favorable range despite this genotype, other variants (LPL, APOE, FADS1/2, ANGPTL3) or lifestyle factors may be dominant.

Interactions

PDE3B sits at the intersection of insulin signaling and adrenergic lipolysis. Its loss-of-function phenotype is most pronounced when catecholamine tone is high (fasting, aerobic exercise, cold exposure) — conditions that would normally activate lipolysis but are partially blunted by PDE3B in wild-type individuals. Variants in ADRB3 (rs4994), which encodes the beta-3 adrenergic receptor, may amplify or attenuate the lipolytic response in PDE3B loss-of-function carriers. Variants affecting lipid clearance (APOE rs429358, LPL rs328) operate downstream of lipolysis on free fatty acid and triglyceride disposal — their combined effect with PDE3B LoF is uncharacterized but potentially additive for triglyceride lowering.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal Enzyme Activity Normal

Full PDE3B enzyme activity — standard lipolysis regulation

PDE3B plays a key gatekeeper role in adipocyte signaling: when adrenaline or glucagon activate the beta-adrenergic pathway, cAMP rises and protein kinase A triggers fat breakdown. PDE3B degrades cAMP to terminate this signal. In CC homozygotes, this brake functions at full strength, which is the normal physiological state. There is no evidence that CC homozygosity is associated with adverse lipid phenotypes on its own — lipid profile in CC individuals depends primarily on other variants (APOE, LPL, FADS1/2, ANGPTL3) and dietary fat composition.

CT Reduced Enzyme Activity Beneficial

One loss-of-function PDE3B copy — elevated HDL, lower triglycerides, favorable fat distribution

The T allele introduces a premature stop codon at position 783 of PDE3B, within the catalytic domain. With one functional and one truncated allele, total PDE3B activity is reduced. In the adipocyte, this means cAMP persists longer when catecholamines signal fat mobilization, sustaining protein kinase A activity and tipping the balance toward lipolysis over fat storage.

Koprulu et al. (2022, PMID 34875679) characterized this variant in 450,562 UK Biobank participants and found significant associations with: lower WHR adjusted for BMI (β = −0.39 SD in women, −0.10 in men; P = 1.41 × 10⁻⁶), lower triglycerides, higher HDL-C, and a statistically significant reduction in cardiovascular disease risk when meta-analyzed. The effect on fat distribution is most pronounced in women, consistent with the known sex specificity of adiposity GWAS findings at the PDE3B locus.

The phenotypic direction — higher HDL, lower TG, favorable fat distribution — is consistently beneficial in large population studies. Effect sizes for a single copy are modest (a few mg/dL for lipids; ~0.10 SD for WHRadjBMI in pooled analyses), but the benefit accrues over a lifetime of modestly different adipocyte biology.

TT Homozygous Loss-of-Function Absent

Two loss-of-function PDE3B copies — markedly enhanced lipolysis and favorable lipid profile

The TT genotype has not been observed in gnomAD v4 (149,118 individuals), which is consistent with Hardy-Weinberg expectations for a variant at 0.06% allele frequency (expected TT frequency ~3.4 per 10 million). Any clinical interpretation for this genotype is extrapolated from the dose-response pattern established in CT heterozygotes and from knockout mouse models showing that full PDE3B deletion disrupts insulin's antilipolytic response (DiPilato et al. 2015, PMID 26031333). Clinically, full loss of PDE3B activity in humans would be expected to impair insulin's ability to suppress lipolysis, potentially leading to elevated free fatty acids after meals — a counterintuitive metabolic consequence of what is otherwise a favorable lipid-lowering genotype.